Canada, Qatar and South Korea Approve PharmaMar’s Zepzelca® in combination with Atezolizumab for First-Line Maintenance Treatment of Small Cell Lung Cancer

On August 3, 2026 PharmaMar (MSE: PHM) reported that health authorities in Canada, Qatar and South Korea have approved Zepzelca (lurbinectedin) in combination with atezolizumab (Tecentriq) for the maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed following first-line induction therapy with atezolizumab, carboplatin and etoposide.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The approvals by the Canada’s Health Products and Food Branch (HPFB), the Health Qatar Ministry of Public Health (MoPH) and the Ministry of Food and Drug Safety of South Korea (MFDS) are based on the positive results from the Phase 3 IMforte[1] trial.

With these latest authorizations, the lurbinectedin–atezolizumab combination is now approved in 18 territories worldwide, including the European Union and the United States.

(Press release, PharmaMar, AUG 3, 2026, View Source [SID1234669614])

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

On August 3, 2026 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, reported financial results and provided operational updates for the quarter ended June 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The recent initiation of Himalayas-1, a global Phase 3 registrational trial, brings us closer to delivering a potentially practice-changing therapy for patients with prostate cancer," said Jacob M. Chacko, M.D., president and chief executive officer. "With rinzimetostat now in Phase 3 and enozertinib approaching a key clinical update in the second half of the year, ORIC has become a diversified, late-stage oncology company with multiple opportunities to create meaningful value for patients while advancing our mission of Overcoming Resistance In Cancer."

Second Quarter 2026 and Other Recent Highlights

Rinzimetostat: a potent and selective allosteric inhibitor of PRC2


Finalized the trial protocol and initiated the Himalayas-1 global Phase 3 registrational trial following End-of-Phase 1 interactions with the FDA and other global health authorities. The Himalayas-1 trial is expected to enroll approximately 600 patients from over 250 sites in 25 countries, randomized 1:1 to receive 400 mg once daily rinzimetostat (with or without food) in combination with darolutamide versus physician’s choice of an androgen receptor (AR) inhibitor or docetaxel. The primary endpoint is radiographic progression-free survival and the key secondary endpoint is overall survival.

Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1. Under the terms of the agreement, the company will conduct and sponsor the Himalayas-1 trial and Bayer will provide their AR inhibitor, NUBEQA (darolutamide), at no cost for use in the trial in combination with rinzimetostat. This agreement does not grant Bayer any license, option, or other rights to rinzimetostat and ORIC retains full global development and commercial rights to rinzimetostat.

Presented preclinical data at AACR (Free AACR Whitepaper) showing PRC2 inhibition reduces prostate tumor adaptability and sustains the benefit derived from AR inhibition, with potential advantages of EED over EZH2 inhibition.

Enozertinib: a brain-penetrant, selective inhibitor targeting EGFR exon 20 insertion mutations and EGFR atypical mutations

Enozertinib is currently being evaluated in Phase 1b trials across the following first-line patient populations with advanced NSCLC:


As a single-agent in patients with EGFR atypical mutations.

As a single-agent in patients with EGFR exon 20 insertion mutations.

In combination with subcutaneous (SC) amivantamab and in combination with chemotherapy in patients with EGFR exon 20 insertion mutations.

Anticipated Program Milestones:

ORIC anticipates the following upcoming milestones:


Rinzimetostat in mCRPC:

2H 2026: Program update

Enozertinib in NSCLC:

October 2026: 1L EGFR atypical monotherapy data to be presented at ESMO (Free ESMO Whitepaper) Congress 2026

2H 2026: 1L EGFR exon 20 insertion monotherapy data and combination data with SC amivantamab

Second Quarter 2026 Financial Results


Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments totaled $387.6 million as of June 30, 2026, which includes $59.9 million in net proceeds raised from healthcare specialist funds during the first quarter under the ATM (at-the-market) program. The company expects its cash and investments to fund the operating plan into 2H 2028.


R&D Expenses: Research and development (R&D) expenses were $36.3 million for the three months ended June 30, 2026, compared to $30.5 million for the three months ended June 30, 2025, an increase of $5.7 million. For the six months ended June 30, 2026, R&D expenses were $67.7 million, compared to $55.2 million for the six months ended June 30, 2025, an increase of $12.5 million. The increases were primarily due to an increase in external expenses related to the advancement of rinzimetostat, offset by lower enozertinib costs due to timing of manufacturing and clinical costs as well as lower preclinical costs.


G&A Expenses: General and administrative (G&A) expenses were $9.0 million for the three months ended June 30, 2026, compared to $8.5 million for the three months ended June 30, 2025, an increase of $0.5 million. For the six months ended June 30, 2026, G&A expenses were $17.2 million, compared to $16.6 million for the six months ended June 30, 2025, an increase of $0.6 million. The increases were primarily due to higher personnel costs and professional services.

(Press release, ORIC Pharmaceuticals, AUG 3, 2026, View Source [SID1234669613])

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

On August 3, 2026 TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) reported its financial results for the second quarter of 2026, along with recent company developments and provided an update on 2026 financial guidance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, stated, "The second quarter of 2026 was another strong quarter for TG Therapeutics. BRIUMVI delivered another outstanding commercial quarter, exceeding our expectations once again and putting us on track to exit 2026 at an approximately $1 billion annualized U.S. BRIUMVI revenue run rate.

Mr. Weiss continued, "Beyond our commercial performance, we continued to expand the long-term opportunity for BRIUMVI with positive Phase 3 ENHANCE results supporting a simplified initiation regimen, encouraging progress in our subcutaneous BRIUMVI program, advancement into myasthenia gravis and schizophrenia, and continued momentum across our azer-cel cell therapy platform. As BRIUMVI continues to grow, it is becoming the foundation of a broader company focused on advancing innovative therapies for immune-mediated diseases. The progress we made this quarter reinforces our confidence in our strategy and our ability to create long-term value for both patients and shareholders."

Recent Highlights & Developments

BRIUMVI (ublituximab-xiiy) Commercialization


BRIUMVI U.S. net product revenue of $227.7 million for the second quarter 2026, representing approximately a 64% increase over the same period last year


Total global revenue of $240.3 million for the second quarter 2026

Subcutaneous BRIUMVI


Announced positive pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability data from a Phase 1 clinical trial evaluating a subcutaneous formulation of ublituximab (the active agent in BRIUMVI) as compared to IV BRIUMVI


Subcutaneous BRIUMVI demonstrated mean bioavailability of greater than 60% relative to IV administration in the Phase 1 trial


PK modeling and simulation informed by the Phase 1 bioavailability data support the quarterly subcutaneous dosing regimen that is being evaluated in the fully enrolled Phase 3 trial


Top-line Phase 3 data is expected year-end 2026 or early 2027

Positive Topline Phase 3 ENHANCE Data


Announced positive topline results from the Phase 3 ENHANCE trial, a randomized, double-blind study evaluating a consolidated single infusion regimen for initiation of BRIUMVI in adults with RMS


The ENHANCE trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI initiation infusion dosing regimen of 150 mg on Day 1 and 450 mg on Day 15 and a consolidated single 600 mg infusion on Day 1, eliminating the need for a Day 15 infusion.

BRIUMVI in Myasthenia Gravis


Announced positive topline phase 1 data for subcutaneous BRIUMVI in patients with myasthenia gravis (MG)


Initiated a potentially registration-directed randomized phase 2 clinical trial evaluating IV BRIUMVI as a maintenance therapy following induction with efgartigimod in adult patients with MG

BRIUMVI in Schizophrenia


Initiated a Phase 2 clinical trial evaluating BRIUMVI in adults with treatment-resistant schizophrenia

2026 Financial Guidance Update


Raises full year 2026 target total global revenue to approximately $950 million


Raises full year 2026 target BRIUMVI U.S. net product revenue to approximately $890 – $905 million


Full year 2026 target operating expense, defined as R&D and SG&A, of approximately $350 – $400 million excluding non-cash compensation, in addition to approximately $100 million in expenses associated with the subcutaneous BRIUMVI manufacturing costs and secondary manufacturer start-up costs

2026 Remaining Development Pipeline Anticipated Milestones


Present full results from the Phase 3 ENHANCE trial combining Day 1 and Day 15 doses of IV BRIUMVI


Present preliminary Phase 1 azer-cel data in Progressive MS in the second half of 2026


Announce topline Phase 3 data for subcutaneous BRIUMVI year-end 2026/first quarter 2027

Financial Results for Second Quarter 2026

Product Revenue, net: Product revenue, net was $235.8 million and $437.1 million for the three and six months ended June 30, 2026, respectively, compared to $138.8 million and $258.5 million for the three and six months ended June 30, 2025, respectively. Product revenue, net consists primarily of net product sales of BRIUMVI in the United States, which totaled $227.7 million and $422.5 million during the three and six months ended June 30, 2026. Also included in product revenue, net for the three and six months ended June 30, 2026 are sales of BRIUMVI to our ex-U.S. licensing partner, Neuraxpharm, of $8.1 million and $14.6 million, respectively.


License, milestone, royalty and other revenue: License, milestone, royalty and other revenue was approximately $4.5 million and $8.1 million for the three and six months ended June 30, 2026, respectively, compared to approximately $2.3 million and $3.5 million for the three and six months ended June 30, 2025. License, milestone, royalty and other revenue for the three and six months ended June 30, 2026 is predominantly comprised of $3.6 million and $6.3 million, respectively, of royalty revenue recognized under the Commercialization Agreement with Neuraxpharm, and $0.9 million and $1.8 million, respectively, of consideration received for development and regulatory activities performed on behalf of Neuraxpharm in accordance with the Commercialization Agreement.

R&D Expenses: Total research and development (R&D) expense was approximately $95.3 million and $143.7 million for the three and six months ended June 30, 2026, compared to $31.8 million and $78.1 million for the three and six months ended June 30, 2025. During the three and six months ended June 30, 2026 we incurred approximately $54.6 million and $58.8 million, respectively related to subcutaneous manufacturing and secondary manufacturer expenses. The period over period increase in R&D was also attributable to higher clinical trial-related expenses associated with our development pipeline during the period

SG&A Expenses: Total selling, general and administrative (SG&A) expense was approximately $82.1 million and $170.3 million for the three and six months ended June 30, 2026, compared to $55.6 million and $105.9 million for the three and six months ended June 30, 2025. The increase in selling, general and administrative costs during the three and six months ended June 30, 2026 was primarily due to an increase in marketing and media spend, and personnel costs associated with the commercialization of BRIUMVI.

Net income: Net income was $7.8 million and $27.6 million for the three and six months ended June 30, 2026, respectively, compared to net income of $28.2 million and $33.2 million for the three and six months ended June 30, 2025.

Cash Position and Financial Guidance: Cash, cash equivalents and investment securities were $612.3 million as of June 30, 2026. We anticipate that our cash, cash equivalents and investment securities as of June 30, 2026, combined with the projected revenues from BRIUMVI, will be sufficient to fund our business based on our current operating plan.

CONFERENCE CALL INFORMATION
The Company will host a conference call today, August 3, 2026, at 8:30 AM ET, to discuss the Company’s financial results from second quarter of 2026.

To participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics. A live audio webcast will be available on the Events page, located within the Investors & Media section, of the Company’s website at View Source An audio recording of the conference call will also be available for a period of 30 days after the call.

ABOUT BRIUMVI (ublituximab-xiiy) 150 mg/6 mL Injection for IV
BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS. BRIUMVI is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses.

BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in several countries outside of the U.S. for the treatment of adult patients with RMS with active disease defined by clinical or imaging features.

A list of authorized specialty distributors can be found at www.briumvi.com.

(Press release, TG Therapeutics, AUG 3, 2026, View Source [SID1234669612])

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

On August 3, 2026 Lantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage AI-driven precision oncology company, reported the formal creation of Open-Medicine AI (OMAI) and the execution of commercial licensing agreements between OMAI and Lantern Pharma. The agreements, which have received Lantern Pharma Board approval, are consistent with the framework outlined in Lantern’s most recent registered direct financing and establish the commercial operating structure for the multi-agentic AI co-scientist platform previously launched as withZeta.ai.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OMAI will continue to advance the multi-agentic architecture, first proven in oncology and rare cancer research, while expanding its application across broader disease areas. The formation of the entity and the licensing arrangements position OMAI for independent growth, while expanding value creation opportunities and preserving strategic alignment with Lantern Pharma’s clinical programs and shareholders.

AI Centers of Excellence in Dallas, Texas and Bengaluru, India

In the first quarter of 2026, Lantern established and staffed an AI Center of Excellence in Bengaluru, India. This center will serve as a core operational hub accelerating the development, refinement, and scaling of the Open-Medicine platform. The Bengaluru team will bring additional specialized talent to the existing team in Dallas (where Lantern is also headquartered). Both sites will focus on functional enhancements in multi-agent systems, computational biology modeling, knowledge engineering, and large-scale scientific curation — furthering Open-Medicine’s ability to deliver production-grade capabilities to researchers and institutions worldwide.

Market Need and Competitive Landscape

The global market for AI-enabled drug discovery and development tools is projected to exceed $10 billion by 2030, with oncology representing the largest therapeutic segment and compound annual growth rates above 30 percent. The underlying need is structural: traditional drug development remains slow, expensive, and poorly suited to the hundreds of rare and complex diseases that lack commercial scale under conventional models. Knowledge remains fragmented across literature, clinical trial databases, institutional archives, and individual expertise, while experimental iteration continues to consume months or years and hundreds of thousands to millions of dollars per cycle.

At the same time, major general-purpose AI companies — including Anthropic and OpenAI — have publicly signaled or begun developing platforms and tools aimed at scientific discovery and drug development. Their entrance validates the long-term importance of AI co-scientists while also highlighting the differentiation required for durable impact. While general models excel at broad reasoning and language, domain-specific multi-agentic systems grounded in curated ontologies, domain-specific computational tools, and disease-area expertise are required to deliver the precision, auditability, and scientific rigor demanded by drug development.

OMAI is uniquely positioned for differentiated value creation at this intersection. Built from the ground up for oncology and rare disease research and drug-development, the platform combines specialized agent roles, recursive investigation modes, living knowledge graphs, and production tools (including blood-brain barrier prediction, multi-omic analytics via ZetaOmics, and generative chemistry capabilities). Its architecture is designed not merely to retrieve information but to generate, stress-test, and harden insights in a manner that mirrors how expert scientific teams actually work – iteratively, collaboratively and focused on actionable results.

Platform Foundation and Expansion Path

OMAI inherits the full multi-agentic system originally commercialized as withZeta.ai, including:

● Coordinated specialist agents spanning medicinal chemistry, computational biology, clinical trial strategy, biomarkers & translational science, clinical oncology, and general research.
● Three research modes (Explorer, Investigator, Reporter) that support rapid exploration through deep multi-source investigation to structured reporting.
● Proprietary rare-cancer knowledge bases and ontologies covering hundreds of disease entities, biomarkers, clinical trials, and literature.
● Expanding computational layers, including ZetaOmics for multi-omic analysis and continued development of parallel swarm intelligence capabilities.

While rare cancers remain a core component, OMAI’s roadmap includes systematic expansion into additional high-need disease areas – especially in collaboration with leading academic and commercial leaders – that experience the same challenges of fragmented knowledge, high failure costs, limited traditional investment and urgency of patient and disease management needs.

"Open-Medicine AI is built to change how medicines are discovered and developed globally, and as a separate company, to pursue dedicated funding and a valuation path distinct from Lantern’s clinical activity and operations." – Panna Sharma, CEO & President of Lantern Pharma

(Press release, Lantern Pharma, AUG 3, 2026, View Source [SID1234669611])

Corporate presentation

On August 3, 2026 Keros therapeutics presented its corporate presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Presentation, Keros Therapeutics, AUG 3, 2026, View Source [SID1234669610])